Obesity pill Contrave is effective but poses risks, FDA reviewers say

12/5/2010 | Wall Street Journal, The

FDA staff members said Orexigen Therapeutics and Takeda Pharmaceutical's weight-loss pill Contrave has achieved one of the agency's requirements for efficacy, but it causes side effects related to hypertension in some obese patients. An advisory panel is scheduled this week to review the drug, which is a combination of antidepressant bupropion and addiction treatment naltrexone.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Food & Drug Associate
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations